Freeline Therapeutics Holdings Valuation

FRLNDelisted Stock  USD 4.31  0.28  6.10%   
At this time, the firm appears to be overvalued. Freeline Therapeutics shows a prevailing Real Value of $3.53 per share. The current price of the firm is $4.31. Our model computes the value of Freeline Therapeutics from reviewing the firm fundamentals such as Shares Owned By Insiders of 1.09 %, shares owned by institutions of 45.88 %, and Current Valuation of 2.78 M as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
4.31
Please note that Freeline Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Freeline Therapeutics is based on 3 months time horizon. Increasing Freeline Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Freeline Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Freeline Stock. However, Freeline Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  4.31 Real  3.53 Hype  4.31 Naive  4.36
The intrinsic value of Freeline Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Freeline Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
3.53
Real Value
4.74
Upside
Estimating the potential upside or downside of Freeline Therapeutics Holdings helps investors to forecast how Freeline stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Freeline Therapeutics more accurately as focusing exclusively on Freeline Therapeutics' fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.033.245.45
Details
Hype
Prediction
LowEstimatedHigh
4.314.314.31
Details
Naive
Forecast
LowNext ValueHigh
4.364.364.36
Details

Freeline Therapeutics Total Value Analysis

Freeline Therapeutics Holdings is currently expected to have valuation of 2.78 M with market capitalization of 28.24 M, debt of 5.92 M, and cash on hands of 90 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Freeline Therapeutics fundamentals before making equity appraisal based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
2.78 M
28.24 M
5.92 M
90 M

Freeline Therapeutics Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Freeline Therapeutics has an asset utilization ratio of 0.72 percent. This suggests that the Company is making $0.007179 for each dollar of assets. An increasing asset utilization means that Freeline Therapeutics Holdings is more efficient with each dollar of assets it utilizes for everyday operations.

Freeline Therapeutics Ownership Allocation

The market capitalization of Freeline Therapeutics is $28.24 Million. 30% of Freeline Therapeutics Holdings outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.

Freeline Therapeutics Profitability Analysis

The company reported the previous year's revenue of 622 K. Net Loss for the year was (49.93 M) with profit before overhead, payroll, taxes, and interest of 0.

About Freeline Therapeutics Valuation

We use absolute and relative valuation methodologies to arrive at the intrinsic value of Freeline Therapeutics Holdings. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Freeline Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Freeline Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Freeline Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Freeline Therapeutics. We calculate exposure to Freeline Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Freeline Therapeutics's related companies.
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom. Freeline Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 235 people.

Freeline Therapeutics Growth Indicators

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
Common Stock Shares OutstandingM
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Other Consideration for investing in Freeline Stock

If you are still planning to invest in Freeline Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Freeline Therapeutics' history and understand the potential risks before investing.
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Transaction History
View history of all your transactions and understand their impact on performance
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences